The DOI matches its Crossref record; 77 of the 77 references it cites were found in a registry or an index.
Molecular diagnostics of neurodegenerative disorders
Open accessAbstract
Molecular diagnostics provide a powerful method to detect and diagnose various neurological diseases such as Alzheimer's and Parkinson's disease. The confirmation of such diagnosis allows early detection and subsequent medical counseling that help specific patients to undergo clinically important drug trials. This provides a medical pathway to have better insight of neurogenesis and eventual cure of the neurodegenerative diseases. In this short review, we present recent advances in molecular diagnostics especially biomarkers and imaging spectroscopy for neurological diseases. We describe advances made in Alzheimer's disease (AD), Parkinson's disease (PD), Amyotrophic lateral sclerosis (ALS) and Huntington's disease (HD), and finally present a perspective on the future directions to provide a framework for further developments and refinements of molecular diagnostics to combat neurodegenerative disorders.
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Figures
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“Diagnosis of neurodegenerative diseases is usually based on subjective cognitive tests in combination with neuroimaging [131–133], but the current techniques are not able to successfully diagnose these diseases in their earlier stages, when the pathology is already present but does not cause symptoms yet.”
From Brain-Derived Neurotrophic Factor in Brain Disorders: Focus on Neuroinflammation (2019) · cites this paper as [132]
Experimental — accuracy not yet measured
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
The Amyloid Hypothesis of Alzheimer’s Disease: Progress and Problems on the Road to Therapeutics
Hardy, J., & Selkoe, D. J. (2002) · Science · doi:10.1126/science.1072994 · Cited by 13,864 · cited 1×
“Proteases that are involved in the breakdown of APP, are α-, β-, and γ- secretases (Hardy and Selkoe, 2002; Rachakonda et al., 2004).”
BackgroundAmyloid oligomers exacerbate tau pathology in a mouse model of tauopathy
Selenica, M.-L. B., Brownlow, M., Jimenez, J. P., Lee, D. C., Pena, G., Dickey, C. A., Gordon, M. N., & Morgan, D. (2013) · Neurodegenerative Diseases · doi:10.1159/000337230 · Cited by 10,359
DeJesus-Hernandez, M., Mackenzie, I. R., Boeve, B. F., Boxer, A. L., Baker, M., Rutherford, N. J., Nicholson, A. M., Finch, N. A., Flynn, H., Adamson, J., et al. (2011) · Neuron · doi:10.1016/j.neuron.2011.09.011 · Cited by 4,936
Hereditary Early-Onset Parkinson's Disease Caused by Mutations in PINK1
Valente, E. M., Abou-Sleiman, P. M., Caputo, V., Muqit, M. M. K., Harvey, K., Gispert, S., Ali, Z., Del Turco, D., Bentivoglio, A. R., Healy, D. G., et al. (2004) · Science · doi:10.1126/science.1096284 · Cited by 3,481 · cited 1×
“This finding provided additional evidence that PINK1 mutations are associated with PARK6 (Valente et al., 2004).”
BackgroundMutations in the DJ-1 Gene Associated with Autosomal Recessive Early-Onset Parkinsonism
Bonifati, V., Rizzu, P., van Baren, M. J., Schaap, O., Breedveld, G. J., Krieger, E., Dekker, M. C. J., Squitieri, F., Ibáñez, P., Joosse, M., et al. (2003) · Science · doi:10.1126/science.1077209 · Cited by 2,854
The ubiquitin pathway in Parkinson's disease
Leroy, E., Boyer, R., Auburger, G. W. J., Leube, B., Ulm, G., Mezey, É., Harta, G., Brownstein, M., Jonnalagada, S., Chernova, T., et al. (1998) · Nature · doi:10.1038/26652 · Cited by 1,599
Alzheimer’s disease β-amyloid peptides are released in association with exosomes
Rajendran, L., Honsho, M., Zahn, T. R., Keller, P., Geiger, K. D., Verkade, P., & Simons, K. (2006) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0603838103 · Cited by 1,343 · cited 1×
“It has been reported that exosomal amyloid peptides accumulate in the brain plaques of AD patients (Rajendran et al., 2006) and tau phosphorylated at Thr-181, an established biomarker for AD, is present at elevated levels in exosomes isolated from cerebrospinal fluid specimens of AD patients with…”
BackgroundPlasma phospholipids identify antecedent memory impairment in older adults
Mapstone, M. E., Cheema, A. K., Fiandaca, M. S., Zhong, X., Mhyre, T. R., MacArthur, L. H., Hall, W. J., Fisher, S. G., Peterson, D. R., Haley, J. M., et al. (2014) · Nature Medicine · doi:10.1038/nm.3466 · Cited by 1,060
Review Article: Genetics of Alzheimer Disease
Bekris, L. M., Yu, C.-E., Bird, T. D., & Tsuang, D. W. (2010) · Journal of Geriatric Psychiatry and Neurology · doi:10.1177/0891988710383571 · Cited by 1,029 · cited 1×
“In addition to the mutations mentioned above, which can cause AD, the E4 allele of the ApoE is associated with the sporadic forms of AD (Bekris et al., 2010).”
BackgroundSaman, S., Kim, W., Raya, M., Visnick, Y., Miro, S., Saman, S., Jackson, B., McKee, A. C., Alvarez, V. E., Lee, N. C. Y., et al. (2012) · Journal of Biological Chemistry · doi:10.1074/jbc.m111.277061 · Cited by 985
Research works printed but not linked: 1
- Duyckaerts, 2003, Lewy bodies, a misleading marker for Parkinson's disease?, Bull. Acad. Natl. Med., 187, 277
Cited by
Sorted by citations
Brain-Derived Neurotrophic Factor in Brain Disorders: Focus on Neuroinflammation
Lima Giacobbo, B., Doorduin, J., Klein, H. C., Dierckx, R. A. J. O., Bromberg, E., & de Vries, E. F. J. (2019) · Molecular Neurobiology · doi:10.1007/s12035-018-1283-6 · Cited by 750
Epidemiology of amyotrophic lateral sclerosis: an update of recent literature
Longinetti, E., & Fang, F. (2019) · Current Opinion in Neurology · doi:10.1097/wco.0000000000000730 · Cited by 620
Brain lipidomics: From functional landscape to clinical significance
Yoon, J. H., Seo, Y., Jo, Y. S., Lee, S., Cho, E., Cazenave-Gassiot, A., Shin, Y.-S., Moon, M. H., An, H. J., Wenk, M. R., et al. (2022) · Science Advances · doi:10.1126/sciadv.adc9317 · Cited by 324
Potential neuroprotective properties of epigallocatechin-3-gallate (EGCG)
Singh, N. A., Mandal, A. K. A., & Khan, Z. A. (2015) · Nutrition Journal · doi:10.1186/s12937-016-0179-4 · Cited by 324
“Neuropathologically, the hallmarks of PD include misfolding and aggregation of α-synuclein protein, damage and loss of dopamine (DA) neurons in the substantia nigra pars compacta (SN) along with oxidative stress caused due to mitochondrial dysfunction [63].”
BackgroundSheinerman, K. S., Toledo, J. B., Tsivinsky, V. G., Irwin, D., Grossman, M., Weintraub, D., Hurtig, H. I., Chen-Plotkin, A., Wolk, D. A., McCluskey, L. F., et al. (2017) · Alzheimer's Research & Therapy · doi:10.1186/s13195-017-0316-0 · Cited by 154
Watson, C. N., Belli, A., & Pietro, V. D. (2019) · Frontiers in Genetics · doi:10.3389/fgene.2019.00364 · Cited by 154
Cano, A., Sánchez-López, E., Ettcheto, M., López-Machado, A., Espina, M., Souto, E. B., Galindo, R., Camins, A., García, M. L., & Turowski, P. (2020) · Nanomedicine · doi:10.2217/nnm-2019-0443 · Cited by 144
Neurotheranostics as Personalized Medicines
Kevadiya, B. D., Ottemann, B. M., Thomas, M. B., Mukadam, I., Nigam, S., McMillan, J., Gorantla, S., Bronich, T. K., Edagwa, B., & Gendelman, H. E. (2019) · Advanced Drug Delivery Reviews · doi:10.1016/j.addr.2018.10.011 · Cited by 124
Rehman, M. U., Sehar, N., Dar, N. J., Khan, A., Arafah, A., Rashid, S., Rashid, S. M., & Ganaie, M. A. (2023) · Neuroscience & Biobehavioral Reviews · doi:10.1016/j.neubiorev.2022.104961 · Cited by 130
Yeung, A. W. K., Tzvetkov, N. T., Georgieva, M. G., Ognyanov, I., Kordos, K., Jóźwik, A., Kühl, T., Perry, G. L., Petralia, M. C., Mazzon, E., et al. (2020) · Antioxidants and Redox Signaling · doi:10.1089/ars.2019.7952 · Cited by 112
“However, according to Agrawal and Biswas (1), in the United States AD, PD, ALS, MS, and HD were affecting populations in millions, 5, 1, 0.03, 0. parkin, protein/nucleic acid deglycase (DJ1) encoded by the PARK7 gene, and mutant a -synuclein in PD; and frataxin in Friedreich ataxia—are associated with mitochondria as…”
InfluentialAlzheimer disease pathology and the cerebrospinal fluid proteome
Dayon, L., Núñez Galindo, A., Wojcik, J., Cominetti, O., Corthésy, J., Oikonomidi, A., Henry, H., Kussmann, M., Migliavacca, E., Severin, I., et al. (2018) · Alzheimer's Research & Therapy · doi:10.1186/s13195-018-0397-4 · Cited by 101
“Several circulating protein markers of neurodegenerative diseases, such as Parkinson’s disease or Alzheimer disease (AD), have been reported [2], but the ones with consistent findings or of current clinical utility are very few [3].”
BackgroundToader, C., Tătaru, C. P., Munteanu, O., Șerban, M., Covache-Busuioc, R.-A., Ciurea, A. V., & Enyedi, M. (2024) · International Journal of Molecular Sciences · doi:10.3390/ijms252312613 · Cited by 112
Exploring the reproducibility of functional connectivity alterations in Parkinson’s disease
Badea, L., Onu, M., Wu, T., Roceanu, A. M., & Bajenaru, O. A. (2017) · PLoS ONE · doi:10.1371/journal.pone.0188196 · Cited by 105
Neuroprotective Properties of Green Tea (Camellia sinensis) in Parkinson’s Disease: A Review
Malar, D. S., Prasanth, M. I., Brimson, J. M., Sharika, R., Sivamaruthi, B. S., Chaiyasut, C., & Tencomnao, T. (2020) · Molecules · doi:10.3390/molecules25173926 · Cited by 97
Doroszkiewicz, J., Groblewska, M., & Mroczko, B. (2022) · International Journal of Molecular Sciences · doi:10.3390/ijms23094610 · Cited by 88
Henríquez, G., Gomez, A., Guerrero, E., & Narayan, M. (2020) · ACS Chemical Neuroscience · doi:10.1021/acschemneuro.0c00381 · Cited by 83
Stem Cell Transplantation Therapy and Neurological Disorders: Current Status and Future Perspectives
Rahman, M. M., Islam, M. R., Islam, M. T., Harun-Or-Rashid, M., Islam, M., Abdullah, S., Uddin, M., Das, S. K., Rahaman, M. S., Ahmed, M., et al. (2022) · Biology · doi:10.3390/biology11010147 · Cited by 82
Evidence to Consider Angiotensin II Receptor Blockers for the Treatment of Early Alzheimer’s Disease
Saavedra, J. M. (2016) · Cellular and Molecular Neurobiology · doi:10.1007/s10571-015-0327-y · Cited by 84
Genetic testing and genetic counseling for amyotrophic lateral sclerosis: an update for clinicians
Roggenbuck, J., Quick, A. D., & Kolb, S. J. (2016) · Genetics in Medicine · doi:10.1038/gim.2016.107 · Cited by 83
Conifers Phytochemicals: A Valuable Forest with Therapeutic Potential
Bhardwaj, K., Sanches-Silva, A. T., Atanassova, M., Sharma, R., Nepovimová, E., Musílek, K., Sharma, R., Alghuthaymi, M. A., Dhanjal, D. S., Nicoletti, M., et al. (2021) · Molecules · doi:10.3390/molecules26103005 · Cited by 78
Modeling neurodegenerative disorders in zebrafish
Bashirzade, A. A., Zabegalov, K. N., Volgin, A. D., Belova, A. S., Demin, K. A., de Abreu, M. S., Babchenko, V. Y., Bashirzade, K. A., Yenkoyan, K. B., Tikhonova, M. A., et al. (2022) · Neuroscience & Biobehavioral Reviews · doi:10.1016/j.neubiorev.2022.104679 · Cited by 71
Ali, M., Timsina, J., Western, D., Liu, M., Beric, A., Budde, J., Do, A., Heo, G., Wang, L., Gentsch, J., et al. (2025) · Neuron · doi:10.1016/j.neuron.2025.02.014 · Cited by 61
Minimally Invasive Nasal Depot (MIND) technique for direct BDNF AntagoNAT delivery to the brain
Padmakumar, S., Jones, G., Pawar, G. N., Khorkova, O., Hsiao, J. H., Kim, J., Amiji, M. M., & Bleier, B. S. (2021) · Journal of Controlled Release · doi:10.1016/j.jconrel.2021.01.027 · Cited by 62
Perspectives on the recent developments with green tea polyphenols in drug discovery.
Li, F., Wang, Y., Li, D., Chen, Y., Qiao, X., Fardous, R., Lewandowski, A., Liu, J., Chan, T. H., & Dou, Q. P. (2018) · PubMed · doi:10.1080/17460441.2018.1465923 · Cited by 56
“PD is neuropathologically characterized by the misfolding and aggregation of α-synuclein protein, damage and loss of dopamine (DA) neurons in the substantia nigra pars compacta (SN), and mitochondrial dysfunction caused by oxidative stress [82].”
BackgroundIslam, F., Islam, M. R., Meem, A. F. K., Nafady, M. H., Islam, M. R., Akter, A., Mitra, S., Alhumaydhi, F. A., Emran, T. B., Khusro, A., et al. (2022) · Chemosphere · doi:10.1016/j.chemosphere.2022.136020 · Cited by 55
RetractedSharma, V., Singh, T. G., Kaur, A., Mannan, A., & Dhiman, S. (2022) · Neurochemical Research · doi:10.1007/s11064-022-03755-1 · Cited by 58
Gautam, A. (2022) · ECS Sensors Plus · doi:10.1149/2754-2726/ac973e · Cited by 50
“Due to its capacity to identify biomarker concentrations in the blood and CSF, as well as its cheaper cost, greater stability, higher sensitivity, and ease of downsizing, electrochemical sensors have received a lot of attention in recent years.(15,16)”
BackgroundKaur, P., Khera, A., Alajangi, H. K., Sharma, A., Jaiswal, P. K., Singh, G., & Barnwal, R. P. (2022) · Molecular Neurobiology · doi:10.1007/s12035-022-03164-z · Cited by 55
A human-on-a-chip approach to tackling rare diseases
de Mello, C. P. P., Rumsey, J. W., Slaughter, V. L., & Hickman, J. J. (2019) · Drug Discovery Today · doi:10.1016/j.drudis.2019.08.001 · Cited by 49
Lin, C., Wen, T.-C., & Setiawan, F. (2020) · Sensors · doi:10.3390/s20143857 · Cited by 48
“In America, 30,000 people su ff er from ALS, 30,000 from HD and o million from PD [6].”
BackgroundModel-based whole-brain perturbational landscape of neurodegenerative diseases
Perl, Y. S., Fittipaldi, S., Campo, C. G., Moguilner, S., Cruzat, J., Fraile-Vazquez, M. E., Herzog, R. A., Kringelbach, M. L., Deco, G., Prado, P., et al. (2023) · eLife · doi:10.7554/elife.83970 · Cited by 47
“These are quantified through positron emission tomography (PET) or plasma, especially in AD ( Agrawal and Biswas, 2015 ).”
Shohag, S., Akhter, S., Islam, M. S., Sarker, T., Sifat, M. K., Rahman, M. M., Islam, M. R., & Sharma, R. (2022) · Oxidative Medicine and Cellular Longevity · doi:10.1155/2022/7743705 · Cited by 49
“Around 5 million Americans endure Alzheimer’s disease, 1 million from Parkinson’s disease, 400000 from multiple sclerosis (MS), 30,000 from amyotrophic lateral sclerosis (ALS), and 3000 from Huntington’s disease in contemporary times (HD) [25].”
Azam, H. M. H., Rößling, R., Geithe, C., Khan, M. M., Dinter, F., Hanack, K., Prüß, H., Husse, B., Roggenbuck, D., Schierack, P., et al. (2024) · Frontiers in Molecular Neuroscience · doi:10.3389/fnmol.2024.1386735 · Cited by 49
Yuen, S. C., Liang, X., Zhu, H., Jia, Y., & Leung, S.-W. (2021) · Alzheimer s Research & Therapy · doi:10.1186/s13195-021-00862-z · Cited by 42
Aghamohammad, S., Hafezi, A., & Rohani, M. (2023) · Biomedicine & Pharmacotherapy · doi:10.1016/j.biopha.2023.114816 · Cited by 40
Recent Developments in Coumarin Derivatives as Neuroprotective Agents
Mishra, P. S., Kumar, A., Kaur, K., & Jaitak, V. (2023) · Current Medicinal Chemistry · doi:10.2174/0929867331666230714160047 · Cited by 39
Dziedzic, A., Miller, E., Saluk-Bijak, J., & Bijak, M. (2020) · International Journal of Molecular Sciences · doi:10.3390/ijms21051852 · Cited by 38
“Thus, there is an urgent need to discover the diagnostic marker of disease activity or disability progression, especially in MS, which is still not curable [40].”
BackgroundLong Non-Coding RNAs: New Insights in Neurodegenerative Diseases
Anilkumar, A., Vij, P., Lopez, S., Leslie, S., Doxtater, K. D., Khan, M. M., Yallapu, M. M., Chauhan, S. C., Maestre, G. E., & Tripathi, M. K. (2024) · International Journal of Molecular Sciences · doi:10.3390/ijms25042268 · Cited by 38
“More-over, postmortem examinations of brain tissue are the gold standard method for accurate confirmation of many NDDs [2,4].”
BackgroundMethodInfluentialTargeting mTORs by omega-3 fatty acids: A possible novel therapeutic strategy for neurodegeneration?
Shirooie, S., Nabavi, S. F., Dehpour, A. R., Belwal, T., Habtemariam, S., Argüelles, S., Sureda, A., Daglia, M., Tomczyk, M., Sobarzo‐Sánchez, E., et al. (2018) · Pharmacological Research · doi:10.1016/j.phrs.2018.07.004 · Cited by 37
“have been devoted to understanding the pathophysiological changes and risk factors of these chronic NDs [1].”
BackgroundHuang, Y., Singh, P., & Kuo, H. (2020) · IEEE Access · doi:10.1109/access.2020.2969806 · Cited by 37
“The experts use positron emission tomography (PET) or single-photon emission computerized tomography (SPECT) scans to evaluate the level of PD [9].”
BackgroundSingh, P. (2020) · Artificial Intelligence in Medicine · doi:10.1016/j.artmed.2020.101838 · Cited by 37
Kabiraj, P., Marin, J. E., Varela-Ramı́rez, A., & Narayan, M. (2016) · ACS Chemical Neuroscience · doi:10.1021/acschemneuro.6b00159 · Cited by 36
Drug Development for Alzheimer’s and Parkinson’s Disease: Where Do We Go Now?
Sequeira, L., Benfeito, S., Fernandes, C., Gaspar, A., Lima, I., Peixoto, J., Alves, C., Machado, C. S., Borges, F., & Chavarria, D. (2024) · Pharmaceutics · doi:10.3390/pharmaceutics16060708 · Cited by 37
“Although the neurons that degenerate in AD are mostly cholinergic [49], glutamatergic neurons are also affected [50].”
BackgroundPharmaceutical prospects of Silymarin for the treatment of neurological patients: an updated insight
Ranjan, S., & Gautam, A. (2023) · Frontiers in Neuroscience · doi:10.3389/fnins.2023.1159806 · Cited by 35
“Due to their multifactorial and complex progression, brain disorders still need a complete understanding of the molecular pathways to develop specific therapeutic targets (Agrawal and Biswas, 2015).”
BackgroundReview of β‐carboline and its derivatives as selective MAO‐A inhibitors
Benny, F., Kumar, S., Jayan, J., Abdelgawad, M. A., Ghoneim, M. M., Kumar, A., Manoharan, A., Ipe, R. S., Sudevan, S. T., & Mathew, B. (2023) · Archiv der Pharmazie · doi:10.1002/ardp.202300091 · Cited by 31
Hadar, A., Milanesi, E., Squassina, A., Niola, P., Chillotti, C., Pasmanik-Chor, M., Yaron, O., Pavel Martasek, E., Rehavi, M., Weissglas‐Volkov, D., et al. (2016) · Translational Psychiatry · doi:10.1038/tp.2016.179 · Cited by 31
Cholesterol and Dementia: A Long and Complicated Relationship
McFarlane, O., & Kędziora–Kornatowska, K. (2019) · Current Aging Science · doi:10.2174/1874609812666190917155400 · Cited by 33
Syndecan-3 as a Novel Biomarker in Alzheimer’s Disease
Hudák, A., Letoha, A., Vízler, C., & Letoha, T. (2022) · International Journal of Molecular Sciences · doi:10.3390/ijms23063407 · Cited by 32
Singh, P. (2020) · Computer Methods and Programs in Biomedicine · doi:10.1016/j.cmpb.2020.105317 · Cited by 30
Point-of-Care Devices Using Disease Biomarkers To Diagnose Neurodegenerative Disorders
Wei, T., Fu, Y., Chang, K., Lin, K., Lin, Y.-J., & Cheng, C. (2017) · Trends in biotechnology · doi:10.1016/j.tibtech.2017.11.004 · Cited by 31
Setiawan, F., Liu, A., & Lin, C. (2022) · IEEE Access · doi:10.1109/access.2022.3158961 · Cited by 31
“In the United States, 30,000 people have ALS, 30,000 have HD, and 1 million have PD [6].”
BackgroundCoronel‐Oliveros, C., González-Gómez, R., Ranasinghe, K. G., Sainz‐Ballesteros, A., Legaz, A., Fittipaldi, S., Cruzat, J., Herzog, R. A., Yener, G., Parra, M. A., et al. (2024) · Alzheimer s & Dementia · doi:10.1002/alz.13788 · Cited by 27
“17 However, these biomarkers present caveats for global settings.”
BackgroundKılıç, Ü., Elibol, B., Uysal, Ö., Kılıç, E., Yuluğ, B., Şakul, A., & Yıldız, G. B. (2018) · Experimental Gerontology · doi:10.1016/j.exger.2018.07.018 · Cited by 28
“In conclusion, we aimed to determine a biomarker for AD in the blood, with a focus on SIRT1 protein and its activity-related proteins (IL7 and TLR4), to overcome limitations for early detection and effective differential diagnosis of this neurodegenerative diseases, as previously done by investigators for different bi…”
Epidemiology of Amyotrophic Lateral Sclerosis
Aktekin, M. R., & Uysal, H. (2020) · Turkish Journal Of Neurology · doi:10.4274/tnd.2020.45549 · Cited by 32
Man’s best friend in life and death: scientific perspectives and challenges of dog brain banking
Sándor, S., Czeibert, K., Salamon, A., & Kubinyi, E. (2021) · GeroScience · doi:10.1007/s11357-021-00373-7 · Cited by 25
Padmakumar, S., Kulkarni, P., Ferris, C. F., Bleier, B. S., & Amiji, M. M. (2022) · Biomedicine & Pharmacotherapy · doi:10.1016/j.biopha.2022.112812 · Cited by 27
Chaperone-Dependent Mechanisms as a Pharmacological Target for Neuroprotection
Воронин, М. В., Абрамова, Е. В., Verbovaya, E. R., Vakhitova, Y. V., & Середенин, С. Б. (2023) · International Journal of Molecular Sciences · doi:10.3390/ijms24010823 · Cited by 27
Network Analysis Identifies Disease-Specific Pathways for Parkinson’s Disease
Monti, C., Colugnat, I., Lopiano, L., Chiò, A., & Alberio, T. (2016) · Molecular Neurobiology · doi:10.1007/s12035-016-0326-0 · Cited by 25
“The analysis of the PD interactor network evidenced four protein complexes: the proteasome 26S, the ETC complex III, the CCT complex and the PPP2A complex.”
InfluentialPharmacological Activities and Molecular Mechanisms of Sinapic Acid in Neurological Disorders
Farzan, M., Abedi, B., Bhia, I., Madanipour, A., Farzan, M., Bhia, M., Aghaei, A., Kheirollahi, I., Motallebi, M., Amini-Khoei, H., et al. (2024) · ACS Chemical Neuroscience · doi:10.1021/acschemneuro.4c00349 · Cited by 24
Molecular basis of chronic neurodegeneration
Agrawal, M. (2019) · Elsevier eBooks · doi:10.1016/b978-0-12-809356-6.00026-5 · Cited by 25
Self-citationSetiawan, F., & Lin, C. (2021) · Brain Sciences · doi:10.3390/brainsci11070902 · Cited by 24
“In the United States, 30,000 people have ALS, 30,000 have HD, and 1 million have PD [6].”
BackgroundNatural polyphenols based new therapeutic avenues for advanced biomedical applications
Agrawal, M. (2015) · Drug Metabolism Reviews · doi:10.3109/03602532.2015.1102933 · Cited by 23
“In the events of ROS-mediated cellular injury, the human body is capable to produce various antioxidants, such as catalase, superoxide dismutase and uric acid to protect the defence system (Agrawal & Biswas, 2015; Zadak et al., 2009).”
BackgroundSelf-citationDNA Methylation Profiles in Whole Blood of Huntington's Disease Patients
Zadel, M., Maver, A., Kovanda, A., & Peterlin, B. (2018) · Frontiers in Neurology · doi:10.3389/fneur.2018.00655 · Cited by 23
Chantsalnyam, T., Siraj, A., Tayara, H., & Chong, K. T. (2021) · Genomics · doi:10.1016/j.ygeno.2021.07.004 · Cited by 22
Elucidating Critical Proteinopathic Mechanisms and Potential Drug Targets in Neurodegeneration
Dar, K. B., Bhat, A. H., Amin, S., Reshi, B. A., Zargar, M. A., Masood, A., & Ganie, S. A. (2019) · Cellular and Molecular Neurobiology · doi:10.1007/s10571-019-00741-0 · Cited by 23
Hajian, R., DeCastro, J., Parkinson, J., Kane, A., Camelo, A. F. R., Chou, P. P., Yang, J., Wong, N., Hernandez, E. D. O., Goldsmith, B. R., et al. (2021) · Advanced Biology · doi:10.1002/adbi.202000594 · Cited by 21
Rouhi, N., Chakeri, Z., Ghorbani Nejad, B., Rahimzadegan, M., Rafi Khezri, M., Kamali, H., & Nosrati, R. (2024) · Heliyon · doi:10.1016/j.heliyon.2024.e37533 · Cited by 20
Targeting amyloid proteins for clinical diagnosis of neurodegenerative diseases
Zhang, S., Dong, H., Bian, J., Li, D., & Liu, C. (2022) · Fundamental Research · doi:10.1016/j.fmre.2022.10.009 · Cited by 23
“…rapidly developed in the last two decades, including structural neuroimaging, functional magnetic resonance imaging (MRI), anatomical verification of neuronal pathology, fluid-based biomarkers diagnosis, genetic markers by genetic sequencing, brain mapping, wearable-sensor recording, et al. [6–8] .”
BackgroundBiswas, J., Gupta, S., Verma, D., & Singh, S. (2017) · Neuroscience · doi:10.1016/j.neuroscience.2017.05.018 · Cited by 21
“To study the disease so far we use diagnostic approaches in Alzheimer’s patients (Agrawal and Biswas, 2015, Shivamurthy et al., 2015), transgenic model, non transgenic pharmacological rodent models (Spires and Hyman, 2005, Lecanu and Papadopoulos, 2013) and in vitro model (Biswas et al., 2016).”
MRI visualization of neuroinflammation using VCAM-1 targeted paramagnetic micelles
Garello, F., Pagoto, A., Arena, F., Buffo, A., Blasi, F., Alberti, D., & Terreno, E. (2017) · Nanomedicine Nanotechnology Biology and Medicine · doi:10.1016/j.nano.2017.10.002 · Cited by 21
A cerebrospinal fluid microRNA analysis: Progressive supranuclear palsy
Nonaka, W., Takata, T., Iwama, H., Komatsubara, S., Kobara, H., Kamada, M., Deguchi, K., Touge, T., Miyamoto, O., Nakamura, T., et al. (2022) · Molecular Medicine Reports · doi:10.3892/mmr.2022.12604 · Cited by 18
Zhang, T., Chen, J., Lü, Y., Yang, X., & Ouyang, Z. (2022) · PLoS ONE · doi:10.1371/journal.pone.0273355 · Cited by 18
“The confirmation of such diagnosis allows early detection and subsequent medical counseling that helps specific patients to undergo clinically important drug trials [63].”
BackgroundImpact of diet-derived signaling molecules on human cognition: exploring the food–brain axis
Rodriguez, R. L., Albeck, J. G., Taha, A. Y., Ori-McKenney, K. M., Recanzone, G. H., Stradleigh, T. W., Hernandez, B. C., Tang, F., Chiang, E. I., & Cruz‐Orengo, L. (2017) · npj Science of Food · doi:10.1038/s41538-017-0002-4 · Cited by 18
“In the case of AD, several genetic factors have been identified including the ε4 allele of the APOE gene, which is a strong risk indicator for both AD and coronary artery disease.(144,145) Both diseases are also associated with sedentary lifestyle and obesity.”
BackgroundParkinson’s disease research: adopting a more human perspective to accelerate advances
Marshall, L. J., & Willett, C. (2018) · Drug Discovery Today · doi:10.1016/j.drudis.2018.09.010 · Cited by 19
Ruiz-Contreras, H. A., Santamarı́a, A., Arellano-Mendoza, M. G., Sánchez‐Chapul, L., Robles-Bañuelos, B., & Rangel‐López, E. (2022) · Neurotoxicity Research · doi:10.1007/s12640-022-00592-6 · Cited by 18
“Although the area where the greatest damage caused in HD is found in the striatum, the damage might also be observed in the white matter and the neocortex (Agrawal and Biswas 2015; Erkkinen et al.”
BackgroundTatullo, M., Codispoti, B., Spagnuolo, G., & Zavan, B. (2019) · Brain Sciences · doi:10.3390/brainsci9120358 · Cited by 17
“This link among neurodegenerative and psychiatric diseases may recognize some common factors, such as the dysregulation of the cytokine system, and the alteration of circadian rhythm [71].”
BackgroundMoguilner, S., Herzog, R. A., Perl, Y. S., Medel, V., Cruzat, J., Coronel, C., Kringelbach, M. L., Deco, G., Ibáñez, A. M., & Tagliazucchi, E. (2024) · Alzheimer s Research & Therapy · doi:10.1186/s13195-024-01449-0 · Cited by 15
“Fourth, dementia diagnosis typically relies on clinical criteria, but biomarkers like amyloid-β and tau proteins measured by PET or plasma are also used [89].”
MethodReport on the Symposium “Molecular Mechanisms Involved in Neurodegeneration”
Pentón‐Rol, G., & Cervantes‐Llanos, M. (2018) · Behavioral Sciences · doi:10.3390/bs8010016 · Cited by 16
Role of Biomarkers in Medicine
Wang, M., & Witzmann, F. A. (2016) · InTech eBooks · doi:10.5772/61449 · Cited by 16
Singh, S., Srivastava, A., Srivastava, P., Dhuriya, Y. K., Pandey, A., Kumar, D., & Rajpurohit, C. S. (2016) · Frontiers in Molecular Biosciences · doi:10.3389/fmolb.2016.00072 · Cited by 14
“Neurodegeneration studies have largely benefited from neuropathology and in-vivo research (Agrawal and Biswas, 2015).”
BackgroundDiagnostic delay among ALS patients: Egyptian study
Rashed, H. R., & Tork, M. A. (2020) · Amyotrophic Lateral Sclerosis and Frontotemporal Degeneration · doi:10.1080/21678421.2020.1763401 · Cited by 14
Cassotta, M. (2022) · ALTEX · doi:10.14573/altex.2203161 · Cited by 14
“…diffusion tensor MRI (Zhang and Burock, 2020), functional MRI (fMRI) (Baggio and Junqué, 2019), transcranial sonography, magnetoencephalography (Agrawal and Biswas, 2015), proton magnetic resonance spectroscopy (PMRS) (Mazuel et al., 2016), and single photon-emission computed tomography…”
BackgroundCruchaga, C., Ali, M., Shen, Y., Do, A. N., Wang, L., Western, D., Liu, M., Beric, A., Budde, J., Gentsch, J., et al. (2024) · Research Square · doi:10.21203/rs.3.rs-3631708/v1 · Cited by 14
Almutary, A. G., Begum, M. Y., Siddiqua, A., Gupta, S., Chauhan, P., Wadhwa, K., Singh, G., Iqbal, D., Padmapriya, G., Kumar, S., et al. (2025) · Molecular Neurobiology · doi:10.1007/s12035-024-04654-y · Cited by 15
“Furthermore, non-neurological symptoms may develop that closely resemble neurological conditions [11, 29, 30].”
Multiple Criteria Optimization (MCO): A gene selection deterministic tool in RStudio
Narvaez-Bandera, I. Y., Suárez-Gómez, D., Isaza, C. E., & Cabrera‐Ríos, M. (2022) · PLoS ONE · doi:10.1371/journal.pone.0262890 · Cited by 12
Nowowiejska, J., Baran, A. M., Hermanowicz, J. M., Sieklucka, B., Krahel, J. A., Kiluk, P., Pawlak, D., & Flisiak, I. (2022) · Journal of Clinical Medicine · doi:10.3390/jcm11092430 · Cited by 12
“Improper GA homeostasis has been suggested in the pathogenesis of AD, PD, HD or ALS [22].”
BackgroundInfluentialPolymerase chain reaction with nearby primers
Гарафутдинов, Р. Р., Galimova, A. A., & Sakhabutdinova, A. R. (2016) · Analytical Biochemistry · doi:10.1016/j.ab.2016.11.017 · Cited by 12
Goudarzi, N., Taheri, Z., Salari, A. M. N., Kazemzadeh, K., & Tafakhori, A. (2025) · Reviews in the Neurosciences · doi:10.1515/revneuro-2024-0125 · Cited by 12
Psoriasis and neurodegenerative diseases—a review
Nowowiejska, J., Baran, A. M., & Flisiak, I. (2022) · Frontiers in Molecular Neuroscience · doi:10.3389/fnmol.2022.917751 · Cited by 10
“Their pathogenesis is different and various parts of the nervous system may be affected by the pathological process but all of them result in the loss of neuronal tissue (Agrawal and Biswas, 2015).”
BackgroundInfluentialPerspective on investigation of neurodegenerative diseases with neurorobotics approaches
Tolu, S., Strohmer, B., & Zahra, O. (2023) · Neuromorphic Computing and Engineering · doi:10.1088/2634-4386/acc2e1 · Cited by 9
Cerebrospinal fluid transcripts may predict shunt surgery responses in normal pressure hydrocephalus
Levin, Z., Leary, O. P., Mora, V., Kant, S., Brown, S., Svokos, K. A., Akbar, U., Serre, T., Klinge, P. M., Fleischmann, A., et al. (2023) · Brain · doi:10.1093/brain/awad109 · Cited by 9
Argentati, C., Tortorella, I., Bazzucchi, M., Emiliani, C., Morena, F., & Martino, S. (2020) · Journal of Personalized Medicine · doi:10.3390/jpm10030115 · Cited by 10
The Diagnostic Potential of Amyloidogenic Proteins
Jin, Y., Vadukul, D. M., Gialama, D., Ge, Y., Thrush, R. J., White, J. T., & Aprile, F. A. (2021) · International Journal of Molecular Sciences · doi:10.3390/ijms22084128 · Cited by 9
Dietary NMN supplementation enhances motor and NMJ function in ALS
Lundt, S., Zhang, N., Polo‐Parada, L., Wang, X., & Ding, S. (2024) · Experimental Neurology · doi:10.1016/j.expneurol.2024.114698 · Cited by 9
Galindo, A. N., Macron, C., Cominetti, O., & Dayon, L. (2019) · Methods in molecular biology · doi:10.1007/978-1-4939-9164-8_6 · Cited by 8
Zhang, H., Zhu, F., Dodge, H. H., Higgins, G. A., Omenn, G. S., Guan, Y., & Initiative, T. A. D. N. (2018) · GigaScience · doi:10.1093/gigascience/giy085 · Cited by 7
Manoharan, N., Jayamurali, D., Sridhar, A., & Govindarajulu, S. N. (2025) · Molecular Biology Reports · doi:10.1007/s11033-025-10384-8 · Cited by 7
Parkinson's disease fluid biomarkers for differential diagnosis of atypical parkinsonian syndromes
Yang, J., Idowu, A., Rosenthal, L. S., & Mao, X. (2022) · Clinical and Translational Discovery · doi:10.1002/ctd2.150 · Cited by 7
Computer Vision Technique for Neuro-image Analysis in Neurodegenerative Diseases:A survey
Khan, Y. F., & Kaushik, B. (2020) · International Conference on Emerging Smart Computing and Informatics (ESCI) · doi:10.1109/esci48226.2020.9167520 · Cited by 7
“Most common types of neurodegenerative diseases are Alzheimer’s diseases (AD), Parkinson’s disease, (PD), Hunting ton’s diseases (HD) and Amyotrophic lateral sclerosis (ALS)[1].”
BackgroundGhazanfary, S., Oroojalian, F., Robati, R. Y., Dadmehr, M., & Sahebkar, A. (2019) · Combinatorial Chemistry & High Throughput Screening · doi:10.2174/1386207322666190930113200 · Cited by 6
Metadata
- Authors
- Agrawal, M., & Biswas, A.
- Affiliations
- University of Arkansas at Little Rock (US)
- University of Notre Dame (US)
- Corresponding author
- Agrawal, Megha
- Venue
- Frontiers in Molecular Biosciences
- Publisher
- Frontiers Media SA
- Published
- 2015-09-22
- Volume
- 2
- Pages
- 54-54
- ISSN
- 2296-889X (ISSN-L)
- PMC
- PMC4585189
- OpenAlex
- W1811596609
- Cited by
- 164
- References
- 77
- Citations by year
- 2026: 6 · 2025: 10 · 2024: 18 · 2023: 24 · 2022: 31 · 2021: 13 · 2020: 17 · 2019: 11 · 2018: 15 · 2017: 7 · 2016: 10 · 2015: 2
- FWCI
- 1.39
- Type
- journal article
- Language
- en
- Open access
- gold
- doi.org
- Licence
- cc-by
- Locations
- Frontiers in Molecular Biosciences (publishedVersion, cc-by)
- Europe PMC (PubMed Central) (publishedVersion, cc-by)
- PubMed Central (publishedVersion, cc-by)
- PubMed (publishedVersion)
- DOAJ (DOAJ: Directory of Open Access Journals) (submittedVersion, cc-by-sa)
- Topics
- Life Sciences › Neuroscience › Cellular and Molecular Neuroscience › Alzheimer's disease research and treatments
- Health Sciences › Medicine › Psychiatry and Mental health › Dementia and Cognitive Impairment Research
- Health Sciences › Medicine › Clinical Neurology › Amyotrophic Lateral Sclerosis Research
- Keywords
- molecular diagnosis, neurodegenerative diseases, Alzheimer's disease, Parkinson's disease, amyotrophic lateral sclerosis, Huntington's disease, biomarkers, hyperspectral imaging, early diagnosis, neurogenesis
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
